Clinical Trial Update: TARGTEPO Treatment for Anemia in PD US Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update for TARGTEPO in anemia of end-stage renal disease; study terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of End Stage Renal Disease

Drugs mentioned

• TARGTEPO

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Anemia of End Stage Renal Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-07-13